微信公众号

官网二维码

中国癌症防治杂志 ›› 2024, Vol. 16 ›› Issue (6): 650-655.doi: 10.3969/j.issn.1674-5671.2024.06.03

• 专家共识 • 上一篇    下一篇

肿瘤临床试验研究参与者补偿管理中国专家共识(2024年版)

  

  1. 中国抗癌协会医学伦理学专业委员会
  • 出版日期:2024-12-25 发布日期:2025-01-03

Chinese expert consensus on compensation management for research participants in clinical trials of cancer (2024 edition)

  • Online:2024-12-25 Published:2025-01-03

摘要: 研究参与者的补偿/补贴是研究参与者因参加临床试验所造成的不便、支出的额外费用、付出的额外时间或提供生物样本等,由试验发起方提供的经济或其他形式补偿。国内外临床试验法规和医学伦理准则中均提到可向研究参与者提供一定补偿,但对于补偿的项目、标准、方式和方法没有明确规定。对于如何把握补偿标准,尚缺乏具体的参考依据。为此,中国抗癌协会医学伦理学专业委员会组织相关专家及人员制定本专家共识。本共识旨在针对上市前、注册类抗肿瘤药物临床试验,为其合理确定研究参与者补偿的类别、标准提供一定参考,并提出补偿的伦理审查建议,以及相关人员或部门的监督措施等。

关键词: 肿瘤临床试验, 研究参与者, 补偿, 专家共识

Abstract: Compensation/allowance for research participants in clinical trials refers to economic or other forms of compensation provided by sponsors for any inconvenience, additional expenses, additional time, and provision of biological samples, associated with the participants. Good clinical practice and medical ethics guidelines, either domestic or international, allow the research participants to be provided with certain compensation. However, there is no clear regulation on the items, standards, methods, and means of compensation; in practice, a specific reference basis is lacking for determining whether or not compensation is appropriate. Therefore, experts and personnel are recruited from the Society of Medical Ethics of China Anti⁃Cancer Association to establish this expert consensus, aiming to provide a reference for determining compensation categories and cost standards for the subjects in clinical trials of premarket and registered anti⁃tumor drugs, and to propose ethical review suggestions for compensation and supervision measures for relevant personnel or departments.

Key words: Clinical trial, Research participants, Compensation, Expert consensus

中图分类号: 

  • R19